Topline Results for Phase 2b PROGRESS Study of Pilavapadin (LX9211) in Diabetic Peripheral Neuropathic Pain (DPNP); 10 mg dose to Advance into Phase 3 Development Leaner organization focused on ...

THE WOODLANDS, Texas (AP) — THE WOODLANDS, Texas (AP) — Lexicon Pharmaceuticals Inc. (LXRX) on Thursday reported a loss of $33.8 million in its fourth quarter. On a per-share basis, the The Woodlands, ...

Lexicon Pharmaceuticals shares are trading lower by 48% Monday morning. The company earlier announced topline results from ...

Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report) today and set a price ...

Pharmaceuticals announced topline results from the PROGRESS Phase 2b study evaluating pilavapadin, an oral, non-opioid ...

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

(RTTNews) - Lexicon Pharmaceuticals, Inc. (LXRX) is scheduled to report topline results from its Phase 2b PROGRESS study evaluating Pilavapadin or LX9211, an oral, non-opioid investigational ...

In this article, we are going to take a look at where Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stands against the other diabetes stocks. About 422 million people worldwide have diabetes ...

Conference call and webcast at 8:00 a.m. ET on Monday, March 3, 2025THE WOODLANDS, Texas, March 02, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the ...